GCTK underwent a major financial restructuring with a dramatic 1,200% reduction in outstanding shares (25.6M to 1.9M) while converting from negative $13M to positive $2.8M stockholders' equity.
The massive share count reduction suggests either a major reverse stock split or significant equity restructuring that fundamentally altered the company's capital structure. The conversion from deeply negative equity to positive equity, combined with reduced total liabilities from $18.9M to $5.0M, indicates either debt restructuring, asset write-offs, or fresh capital injection that has stabilized the balance sheet.
The company's financial position improved dramatically with stockholders' equity swinging from negative $13.0M to positive $2.8M and total liabilities declining 73.5% to $5.0M, while cash increased 31% to $7.4M. However, operating cash flow worsened by 22% to negative $15.2M and net losses remain substantial at $19.4M, though slightly improved from the prior year's $22.6M loss. The overall picture suggests a major balance sheet restructuring that has temporarily stabilized the company's financial position, but underlying operational cash burn remains a significant concern for this medical device company still in development phase.
Current liabilities surged 274.4% — significant near-term obligations; verify ability to meet short-term debt.
Equity base grew 121.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Liabilities reduced 73.5% — deleveraging improves balance sheet strength and financial flexibility.
SG&A reduced 66.5% — improved cost efficiency or headcount reduction improving operating margins.
Inventory surged 53.8% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Current assets grew 32.9% — improving short-term liquidity or inventory/receivables build.
Asset base grew 32.1% — expansion through organic growth, acquisitions, or capital deployment.
Cash position surged 31.4% — strong cash generation or capital raise providing significant financial cushion.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Net income grew 14.2% — bottom-line growth signals improving overall business health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →